SG11202105566TA - Immune activating multispecific antigen-binding molecules and uses thereof - Google Patents
Immune activating multispecific antigen-binding molecules and uses thereofInfo
- Publication number
- SG11202105566TA SG11202105566TA SG11202105566TA SG11202105566TA SG11202105566TA SG 11202105566T A SG11202105566T A SG 11202105566TA SG 11202105566T A SG11202105566T A SG 11202105566TA SG 11202105566T A SG11202105566T A SG 11202105566TA SG 11202105566T A SG11202105566T A SG 11202105566TA
- Authority
- SG
- Singapore
- Prior art keywords
- binding molecules
- multispecific antigen
- immune activating
- immune
- activating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020062357 | 2020-03-31 | ||
PCT/JP2021/013456 WO2021200896A1 (en) | 2020-03-31 | 2021-03-30 | Immune activating multispecific antigen-binding molecules and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202105566TA true SG11202105566TA (en) | 2021-11-29 |
Family
ID=77928944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202105566TA SG11202105566TA (en) | 2020-03-31 | 2021-03-30 | Immune activating multispecific antigen-binding molecules and uses thereof |
Country Status (9)
Country | Link |
---|---|
US (1) | US20230147840A1 (zh) |
EP (1) | EP4126958A1 (zh) |
JP (1) | JP2021175391A (zh) |
KR (1) | KR20220161156A (zh) |
CN (1) | CN115315447A (zh) |
AR (1) | AR121692A1 (zh) |
SG (1) | SG11202105566TA (zh) |
TW (1) | TW202204410A (zh) |
WO (1) | WO2021200896A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113278076A (zh) | 2013-11-11 | 2021-08-20 | 中外制药株式会社 | 含有改变了抗体可变区的抗原结合分子 |
JP7357616B2 (ja) | 2017-12-05 | 2023-10-06 | 中外製薬株式会社 | Cd3およびcd137に結合する改変された抗体可変領域を含む抗原結合分子 |
WO2023036043A1 (zh) * | 2021-09-09 | 2023-03-16 | 广东东阳光药业有限公司 | 抗癌结合分子及其应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103429737B (zh) | 2010-11-30 | 2020-07-14 | 中外制药株式会社 | 细胞毒诱导治疗剂 |
US20140242077A1 (en) | 2013-01-23 | 2014-08-28 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
IL247715B (en) | 2014-04-07 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | Antigen binding molecules that activate the immune system |
MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
JP7357616B2 (ja) * | 2017-12-05 | 2023-10-06 | 中外製薬株式会社 | Cd3およびcd137に結合する改変された抗体可変領域を含む抗原結合分子 |
BR112021005472A2 (pt) * | 2018-09-28 | 2021-06-15 | Chugai Seiyaku Kabushiki Kaisha | molécula de ligação ao antígeno compreendendo uma região variável do anticorpo alterada |
PE20211072A1 (es) * | 2018-09-28 | 2021-06-09 | Chugai Pharmaceutical Co Ltd | Moleculas de union a antigeno capaces de unirse al cumulo de diferenciacion 3 (cd3) y al cumulo de diferenciacion 137 (cd137) pero no simultaneamente |
-
2021
- 2021-03-30 JP JP2021056390A patent/JP2021175391A/ja active Pending
- 2021-03-30 AR ARP210100788A patent/AR121692A1/es unknown
- 2021-03-30 CN CN202180020903.4A patent/CN115315447A/zh active Pending
- 2021-03-30 EP EP21780692.6A patent/EP4126958A1/en active Pending
- 2021-03-30 SG SG11202105566TA patent/SG11202105566TA/en unknown
- 2021-03-30 KR KR1020217031417A patent/KR20220161156A/ko unknown
- 2021-03-30 WO PCT/JP2021/013456 patent/WO2021200896A1/en unknown
- 2021-03-30 TW TW110111557A patent/TW202204410A/zh unknown
- 2021-03-30 US US17/914,855 patent/US20230147840A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TW202204410A (zh) | 2022-02-01 |
CN115315447A (zh) | 2022-11-08 |
KR20220161156A (ko) | 2022-12-06 |
EP4126958A1 (en) | 2023-02-08 |
WO2021200896A1 (en) | 2021-10-07 |
AR121692A1 (es) | 2022-06-29 |
US20230147840A1 (en) | 2023-05-11 |
JP2021175391A (ja) | 2021-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202105302PA (en) | Dll3-targeting multispecific antigen-binding molecules and uses thereof | |
IL313163A (en) | Multispecific antigen binding molecules and their uses | |
SG11202105566TA (en) | Immune activating multispecific antigen-binding molecules and uses thereof | |
IL281568A (en) | Collagen-local immunomodulatory molecules and their use | |
PL3818086T3 (pl) | Leczenie i zapobieganie nowotworom złośliwym z zastosowaniem cząsteczek wiążących antygen HER3 | |
EP3265575A4 (en) | Cd20 binding molecules and uses thereof | |
EP3518972A4 (en) | ANTIGEN BINDING MOLECULES AND THEIR METHODS OF USE | |
SG11202104264TA (en) | Claudin-6 targeting multispecific antigen-binding molecules and uses thereof | |
ZA201806597B (en) | Ilt7 binding molecules and methods of using the same | |
HK1248721A1 (zh) | 抗體分子及其用途 | |
IL313238A (en) | Claudin 6 antibodies and methods of cancer treatment | |
EP3596103A4 (en) | COMPOSITIONS AND PROCESSES INVOLVING PROBIOTIC MOLECULES | |
EP3484488C0 (en) | ANTIGEN BINDING MOLECULES AND RELATED METHODS OF USE | |
IL278832A (en) | Improved molecules that bind 41GP | |
HK1245778A1 (zh) | 用於治療原發性癌症和癌症擴散的小分子 | |
GB201720426D0 (en) | CD47 and BCMA antigen-binding molecules | |
GB201621591D0 (en) | Antibody molecules and method | |
EP4114856A4 (en) | ANTIGEN BINDING MOLECULES AND USES THEREOF | |
IL311096A (en) | Antigen binding molecules and their uses | |
ZA201904626B (en) | Cancer treatment method and composition | |
IL311510A (en) | D3 binding molecules and uses thereof | |
IL285585A (en) | fcmr-binding molecules and their uses | |
AU2020900632A0 (en) | Antigen-binding molecules and uses thereof | |
GB201612534D0 (en) | Antibodies and related molecules and uses thereof | |
GB201604378D0 (en) | Antibodies and related molecules and uses thereof |